No­var­tis’ Kisqali to go head-to-head with Pfiz­er’s Ibrance; USC joins re­gion­al biotech al­liance

⇨ No­var­tis said on Thurs­day that Kisqali (ri­bo­ci­clib) had been OK’d by EU reg­u­la­tors for front­line breast can­cer, set­ting up a di­rect ri­val­ry with Pfiz­er’s Ibrance. That’s an­oth­er boost for No­var­tis’ crit­i­cal on­col­o­gy group.

⇨ Sam­sung Bioepis has claimed brag­ging rights as the first of the biosim­i­lars mak­ers to land an EU ap­proval for all three an­ti-TNF-α block­busters. The OK for its Hu­mi­ra knock­off just land­ed and the Ko­re­an com­pa­ny won ap­proval for copy­cats of En­brel and Rem­i­cade last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER